Genomate Health
AI NativeThe right drug. The first time. Every time.TM Pioneering Digital Drug Assignment for Precision Oncology.
Est 2022|Raised $12.6M
The right drug. The first time. Every time.TM Pioneering Digital Drug Assignment for Precision Oncology.
Published Jul 14, 2026
A Glassdoor listing indicates very limited employee review volume (for example, only a very small number of reviews visible at the time of data collection). This is insufficient to draw conclusions about culture or operational risk but is a datapoint that stakeholders sometimes monitor.
The vendor hosts patient-story style content describing application to specific cancer profiles.
Critical evaluation: These narratives are useful for understanding workflow and possible outcomes but are not independently verified case studies and may present favorable individual outcomes rather than representative performance across a patient population.
Most plausible ICPs (inferred):
Get a comprehensive analysis of Genomate Health including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →Across major B2B review platforms, Genomate Health does not appear to have readily accessible, product-specific review pages in the results surfaced during this research session.
This limited presence on review platforms requires additional due diligence by potential purchasers because public user-review evidence is sparse.
The vendor’s website contains claims such as being "trusted by" a community of patients, oncologists, or partners; however, specific customer names and independently verifiable third-party quotes are limited in the surfaced pages.
Balanced summary: The vendor provides publications and partnership announcements that indicate relevance and institutional engagement, but mainstream review-platform evidence and independent customer testimonials are limited. Procurement teams should plan for reference checks, pilot evaluations, and validation studies as part of vendor assessment.
The vendor highlights a study referenced in a peer-reviewed publication described as a real-world retrospective analysis of a modest cohort of lung cancer patients spanning multiple years, assessing whether therapies aligned with DDA recommendations correlated with improved outcomes.
Vendor-presented highlights include stratification of targeted agents by DDA score thresholds and statements that higher DDA scores were associated with improved outcomes (PFS/OS/ORR/DCR).
Critical evaluation / limitations to flag:
Press materials describe a partnership involving Genomate/Oncompass to develop oncology NGS reporting workflows for a consortium of multiple European hospitals.
Critical evaluation:
Genomate Health provides Genomate®, a precision-oncology clinical decision support product that analyzes a patient’s tumor molecular profile and generates a ranked list of targeted therapies designed to assist oncologists in selecting treatments that may be more appropriate than single-biomarker rules alone. The vendor describes the approach as a knowledge-based computational reasoning system that aims to provide interpretable outputs rather than opaque machine-learning scores.
Key product concepts surfaced in public materials:
Important caveat (regulatory/claims): Genomate’s site states that its reports are clinical decision support and that related statements have not been evaluated by the U.S. FDA as presented on the site. This affects how organizations should interpret claims of clinical benefit and reported accuracy.
Genomate Health appears oriented primarily toward:
Public vendor messaging highlights: synthesis across multiple biomarkers, an interpretable reasoning approach, and an aim to scale interpretation workflows beyond manual tumor boards. These are vendor positions and should be evaluated against independent evidence.